We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics
ARQT

78 hedge funds and large institutions have $1.15B invested in Arcutis Biotherapeutics in 2020 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 33 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 8

175% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 12

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

24% more funds holding

Funds holding: 63 → 78 (+15)

13% more capital invested

Capital invested by funds: $1.02B → $1.15B (+$135M)

2.88% more ownership

Funds ownership: 91.03% → 93.91% (+2.9%)

Holders
78
Holders Change
+15
Holders Change %
+23.81%
% of All Funds
1.38%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
24
Increased
33
Reduced
12
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$34.3M
2
BlackRock
BlackRock
New York
+$20.5M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$20.4M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$20M
5
State Street
State Street
Massachusetts
+$14M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$17.8M
2
VC
Vivo Capital
California
-$6.03M
3
Ameriprise
Ameriprise
Minnesota
-$4.15M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$1.47M
5
Stifel Financial
Stifel Financial
Missouri
-$696K
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
26
Ameriprise
Minnesota
$3.24M -$4.15M -169,329 -60%
OCA
27
Octagon Capital Advisors
New York
$2.81M +$2.45M +100,000 New
Marshall Wace
28
Marshall Wace
United Kingdom
$2.22M +$1.93M +78,973 New
AA
29
ALPS Advisors
Colorado
$1.94M +$498K +20,331 +42%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$1.87M +$243K +9,916 +18%
ACM
31
Altium Capital Management
New York
$1.77M +$1.54M +62,962 New
LCM
32
Laurion Capital Management
New York
$1.41M – – –
Squarepoint
33
Squarepoint
New York
$1.38M +$1.2M +49,082 New
Two Sigma Investments
34
Two Sigma Investments
New York
$1.37M +$1.2M +48,830 New
California Public Employees Retirement System
35
California Public Employees Retirement System
California
$1.14M -$6.79K -277 -0.7%
Ensign Peak Advisors
36
Ensign Peak Advisors
Utah
$1.09M +$410K +16,728 +76%
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$881K +$97.1K +3,965 +14%
Two Sigma Advisers
38
Two Sigma Advisers
New York
$824K +$718K +29,300 New
State of Wisconsin Investment Board
39
State of Wisconsin Investment Board
Wisconsin
$712K +$228K +9,300 +58%
CS
40
Credit Suisse
Switzerland
$692K +$603K +24,618 New
Swiss National Bank
41
Swiss National Bank
Switzerland
$684K +$73.5K +3,000 +14%
Norges Bank
42
Norges Bank
Norway
$594K – – –
MWNA
43
Marshall Wace North America
New York
$581K +$506K +20,661 New
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$565K +$76.3K +3,113 +18%
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$512K +$216K +8,800 +94%
AllianceBernstein
46
AllianceBernstein
Tennessee
$444K -$1.47M -59,864 -79%
DekaBank Deutsche Girozentrale
47
DekaBank Deutsche Girozentrale
Germany
$358K +$304K +12,400 New
OQS
48
Occudo Quantitative Strategies
Florida
$352K +$307K +12,521 New
Manulife (Manufacturers Life Insurance)
49
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$340K +$56.6K +2,311 +24%
Osaic Holdings
50
Osaic Holdings
Arizona
$336K +$283K +11,561 +2,890%
1
2
3 4

ARQT Hedge Fund Activity: Q4 2020 in Review

78 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q4 2020, worth a combined $1.15B — up 13% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ARQT positions and 8 closed out — a net gain of 16 holders — while 33 added to existing stakes and 12 trimmed.

The largest buyer was OrbiMed, adding an estimated $34.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $17.8M.

  • 78 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q4 2020, up from 63 in Q3 2020.
  • Funds reported $1.15B of Arcutis Biotherapeutics stock for Q4 2020, up 13% quarter-over-quarter.
  • 24 funds opened new Arcutis Biotherapeutics positions in Q4 2020 and 8 closed out, a net change of +16 holders.
  • The largest Arcutis Biotherapeutics buyer in Q4 2020 was OrbiMed, an estimated $34.3M added.
  • The largest Arcutis Biotherapeutics seller in Q4 2020 was T. Rowe Price Associates, an estimated $17.8M sold.

Based on aggregated 13F filings for Q4 2020.